179 related articles for article (PubMed ID: 22191531)
1. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.
Echols RM
Ann N Y Acad Sci; 2011 Dec; 1241():153-61. PubMed ID: 22191531
[TBL] [Abstract][Full Text] [Related]
2. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing.
Gleason PP; Walters C; Heaton AH; Schafer JA
J Manag Care Pharm; 2007 Jun; 13(5):420-5. PubMed ID: 17605513
[TBL] [Abstract][Full Text] [Related]
3. Telithromycin. Aventis Pharma.
Johnson AP
Curr Opin Investig Drugs; 2001 Dec; 2(12):1691-701. PubMed ID: 11892930
[TBL] [Abstract][Full Text] [Related]
4. The FDA and the case of Ketek.
Ross DB
N Engl J Med; 2007 Apr; 356(16):1601-4. PubMed ID: 17442902
[No Abstract] [Full Text] [Related]
5. Ketek--the FDA perspective.
Soreth J; Cox E; Kweder S; Jenkins J; Galson S
N Engl J Med; 2007 Apr; 356(16):1675-6. PubMed ID: 17442912
[No Abstract] [Full Text] [Related]
6. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
7. Limit Ketek to pneumonia, experts advise: advisers urge black-box warning.
Young D
Am J Health Syst Pharm; 2007 Jan; 64(2):124-5. PubMed ID: 17215452
[No Abstract] [Full Text] [Related]
8. The wobbly status of ketolides: where do we stand?
Georgopapadakou NH
Expert Opin Investig Drugs; 2014 Oct; 23(10):1313-9. PubMed ID: 25154307
[TBL] [Abstract][Full Text] [Related]
9. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
10. Fraud, errors taint a key study of widely used Sanofi drug; despite some faked results, FDA approves antibiotic; one doctor's cocaine use; company defends safety.
Mathews AW
Wall St J (East Ed); 2006 May; ():A1, A12. PubMed ID: 16838449
[No Abstract] [Full Text] [Related]
11. Telithromycin and the FDA: implications for the future.
Shlaes DM; Moellering RC
Lancet Infect Dis; 2008 Feb; 8(2):83-5. PubMed ID: 18222155
[No Abstract] [Full Text] [Related]
12. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
Goldman SA
Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
[TBL] [Abstract][Full Text] [Related]
13. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
14. FDA under pressure to relax drug rules.
Ledford H
Nature; 2012 Dec; 492(7427):19. PubMed ID: 23222585
[No Abstract] [Full Text] [Related]
15. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
[TBL] [Abstract][Full Text] [Related]
16. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
[No Abstract] [Full Text] [Related]
17. Telithromycin and acute liver failure.
Graham DJ
N Engl J Med; 2006 Nov; 355(21):2260-1. PubMed ID: 17124030
[No Abstract] [Full Text] [Related]
18. The FDA Breakthrough-Drug Designation - Four Years of Experience.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
[No Abstract] [Full Text] [Related]
19. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
20. They are from the government and they really are here to help you.
Woosley RL
J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
[No Abstract] [Full Text] [Related]
[Next] [New Search]